Prime Medicine Inc (PRME) Options

PRME under $2

PRME, under $

Super super undervalued..
Recent PSTX - Roche deal should have made this run? Atleast given it also recently partnered with BMS... makes zero sense.
Is a clear validation CRISPR genome editing is hot in cancer cell therapy.
Waiting for a sign....

PRME under $5

PRME new 52 week low

PRME: Glad I grabbed a chunk of THIS ONE!!!!

"Under the terms of the agreement, Prime Medicine will receive a $55 million upfront payment and a $55 million equity investment from Bristol Myers Squibb. Prime Medicine is also eligible to receive more than $3.5 billion in milestones,..."

"On the Effective Date, the Company entered into the Purchase Agreement with BMS, pursuant to which the Company agreed to issue and sell, and BMS agreed to purchase, in an unregistered offering (the “Offering”), 11,006,163 shares [...] for an aggregate purchase price of $55.0 million..."

PRME new 52=week low

K. I'm in!

DAKT

You are amazing Monk. Any recommendations

PRME under $5

PRME new 52 week low

PRME under $6

PRME under $10:

Great post
Friday Cathie Wood bought more shares for her flagship Ark Fund (ARKK)
I think she has been buying on the decline
She isn’t particularly interested in how well or how lousy the management controls costs it’s the potential she believes exists
There are about a dozen, if not more, listed gene editing companies
Not all will make it before they run out of money and have to raise more operating capital
Notice the $2 to $4 bounces on the way to lower lows

PRME under $10

PRME vs Tome vs Tessera vs NTLA vs CRSP vs...!

They fact this article needs to be written could mean a legal battle is coming https://www.nature.com/articles/s41587-024-02208-0

This $500M company burns $200M a year. These PhDs have been spoiled by Wall St. when money was cheap. Who wants to be their sugar daddy?

I'm sure in the (near) future they will (functionally) cure (rare) diseases, but not before they dilute a whole bunch more.

The CEO has been contently telling investors how easy it would be to bring in funding through partnerships and how difficult capital markets are. Yet they did a secondary. He needs to go. Also, I don't think their IP is gatekeeping others.